CareDx Inc. announced that it has received CE mark approval for its AlloSeq cfDNA kit, making it broadly available to transplant patients and clinicians. AlloSeq cfDNA is an innovative kit based solution, run on next generation sequencing (NGS) platforms, that enables measurement of dd-cfDNA in labs outside of the US. CareDx launched AlloSeq cfDNA during the European Society for Organ Transplantation (ESOT) Congress.